Literature DB >> 10213726

Motor neurone disease.

P J Shaw1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10213726      PMCID： PMC1115517          DOI： 10.1136/bmj.318.7191.1118

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  28 in total

1.  Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.

Authors:  J D Rothstein; M Van Kammen; A I Levey; L J Martin; R W Kuncl
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

Review 2.  Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice.

Authors:  R H Brown
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

Review 3.  Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis.

Authors:  P J Shaw; C J Eggett
Journal:  J Neurol       Date:  2000-03       Impact factor: 4.849

Review 4.  Oxidative stress and motor neurone disease.

Authors:  M R Cookson; P J Shaw
Journal:  Brain Pathol       Date:  1999-01       Impact factor: 6.508

5.  Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease.

Authors:  P Ince; N Stout; P Shaw; J Slade; W Hunziker; C W Heizmann; K G Baimbridge
Journal:  Neuropathol Appl Neurobiol       Date:  1993-08       Impact factor: 8.090

6.  Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35.

Authors:  A Hentati; K Bejaoui; M A Pericak-Vance; F Hentati; M C Speer; W Y Hung; D A Figlewicz; J Haines; J Rimmler; C Ben Hamida
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

7.  Oxidative damage to protein in sporadic motor neuron disease spinal cord.

Authors:  P J Shaw; P G Ince; G Falkous; D Mantle
Journal:  Ann Neurol       Date:  1995-10       Impact factor: 10.422

8.  Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis.

Authors:  E S Louwerse; G J Weverling; P M Bossuyt; F E Meyjes; J M de Jong
Journal:  Arch Neurol       Date:  1995-06

9.  Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis.

Authors:  D A Figlewicz; A Krizus; M G Martinoli; V Meininger; M Dib; G A Rouleau; J P Julien
Journal:  Hum Mol Genet       Date:  1994-10       Impact factor: 6.150

10.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

Authors:  D R Rosen; T Siddique; D Patterson; D A Figlewicz; P Sapp; A Hentati; D Donaldson; J Goto; J P O'Regan; H X Deng
Journal:  Nature       Date:  1993-03-04       Impact factor: 49.962
View more
  10 in total

1.  An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1.

Authors:  Stefania Guareschi; Emanuela Cova; Cristina Cereda; Mauro Ceroni; Elena Donetti; Daryl A Bosco; Davide Trotti; Piera Pasinelli
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-13       Impact factor: 11.205

2.  Adeno-associated virus-mediated delivery of glial cell line-derived neurotrophic factor protects motor neuron-like cells from apoptosis.

Authors:  S D Keir; X Xiao; J Li; P G Kennedy
Journal:  J Neurovirol       Date:  2001-10       Impact factor: 2.643

Review 3.  Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.

Authors:  Eleanor James; Cathy Ellis; Ruth Brassington; Sivakumar Sathasivam; Carolyn A Young
Journal:  Cochrane Database Syst Rev       Date:  2022-05-20

4.  The legs at odd angles (Loa) mutation in cytoplasmic dynein ameliorates mitochondrial function in SOD1G93A mouse model for motor neuron disease.

Authors:  Ali Morsi El-Kadi; Virginie Bros-Facer; Wenhan Deng; Amelia Philpott; Eleanor Stoddart; Gareth Banks; Graham S Jackson; Elizabeth M C Fisher; Michael R Duchen; Linda Greensmith; Anthony L Moore; Majid Hafezparast
Journal:  J Biol Chem       Date:  2010-04-09       Impact factor: 5.157

5.  One universal common endpoint in mouse models of amyotrophic lateral sclerosis.

Authors:  Jesse A Solomon; Mark A Tarnopolsky; Mazen J Hamadeh
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

Review 6.  Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Chris Gibbons; Francesco Pagnini; Tim Friede; Carolyn A Young
Journal:  Cochrane Database Syst Rev       Date:  2018-01-02

7.  A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice.

Authors:  Dairin Kieran; Majid Hafezparast; Stephanie Bohnert; James R T Dick; Joanne Martin; Giampietro Schiavo; Elizabeth M C Fisher; Linda Greensmith
Journal:  J Cell Biol       Date:  2005-05-23       Impact factor: 10.539

8.  A(a)LS: Ammonia-induced amyotrophic lateral sclerosis.

Authors:  Bhavin Parekh
Journal:  F1000Res       Date:  2015-05-14

Review 9.  The Potential Connection between Molecular Changes and Biomarkers Related to ALS and the Development and Regeneration of CNS.

Authors:  Damjan Glavač; Miranda Mladinić; Jelena Ban; Graciela L Mazzone; Cynthia Sámano; Ivana Tomljanović; Gregor Jezernik; Metka Ravnik-Glavač
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

10.  The impact on the family carer of motor neurone disease and intervention with noninvasive ventilation.

Authors:  Susan K Baxter; Wendy O Baird; Sue Thompson; Stephen M Bianchi; Stephen J Walters; Ellen Lee; Sam H Ahmedzai; Alison Proctor; Pamela J Shaw; Christopher J McDermott
Journal:  J Palliat Med       Date:  2013-11-16       Impact factor: 2.947
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.